Minority News
The world you see depends upon the news you get. ®
May 19, 2024
Energy Vault Holdings, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08   •     •   Aramco and Spiritus to Advance Direct Air Capture Technology, Investment by Aramco Ventures   •     •   May and Stanley Smith Charitable Trust Partners with American Indian College Fund to Support Native Student Veterans   •     •   The AZEK Company Receives NYSE Notice Regarding Filing of Form 10-Q for the Fiscal Quarter Ended March 31, 2024   •     •   Federal, provincial and territorial ministers gather to support culture and heritage at annual meeting   •     •   Angels Helpers NYC 2024 Charity Gala Raises Funds for Harlem School of the Arts, Highbridge Voices   •     •   Upneeq® Wins 2024 Shape Skin Award, “Best for Lift”, in the Professional Treatment Category   •     •   Historic Inaugural Class Graduates from OSU College of Osteopathic Medicine at the Cherokee Nation   •     •   HERImpact: Entrepreneurship for Impact Program Kicks Off in Chicago, Empowering Women Entrepreneurs   •     •   Dillard’s, Inc. Announces $0.25 Cash Dividend   •     •   Rockwell Institute Celebrates Highest Real Estate Exam Pass Rates for First-Time Test Takers in the State of Washington   •     •   WOMEN'S HEALTHCARE COMPANY WATKINS-CONTI RECEIVES FDA 510(K) CLEARANCE FOR NEW STRESS URINARY INCONTINENCE DEVICE YŌNI.FIT&  •     •   Xylem Inc. Declares Second Quarter Dividend of 36 Cents per Share   •     •   Red Door Community Raises more than $300,000 at Their Annual Luncheon Celebrating Women Working and Living with Cancer   •     •   Historic Bellevue House reopens   •     •   L.A. Care and Blue Shield of California Promise Health Plans Unveil New, Vibrant Community Resource Center in Panorama City with  •     •   Sacred Heart Celebrates 125th Anniversary   •     •   After Launching Massive Camp Giveaway for NYC Families Affected by "Summer Rising" Crisis, Brains & Motion Education (BAM!)   •     •   Avangrid to Be Acquired by Iberdrola   •     •   Statement by the Prime Minister on Tamil Genocide Remembrance Day   •  
HOME SEARCH SUBSCRIBE CONTACT

Soleo Health Selected as a Specialty Pharmacy Partner of RYPLAZIM® for Plasminogen Deficiency Type 1 (PLGD-1) Treatment

FRISCO, Texas , May 06 /Businesswire/ - Soleo Health, an innovative leader and national provider of complex specialty pharmacy services for treating rare- and ultra-rare diseases, announced today it has been named a limited distribution specialty pharmacy partner to dispense RYPLAZIM® (plasminogen, human-tvmh), manufactured by Kedrion Biopharma.

RYPLAZIM is the first and only Food & Drug Administration (FDA)-approved treatment for supporting the approximately 500 people in the U.S. affected by plasminogen deficiency type 1 (PLGD-1). Considered an ultra-rare disease, PLGD-1 leads to reduced plasminogen activity levels in the body, often resulting in fibrinous lesions on various organs. Approximately 81% of patients develop lesions on one or both eyes as their primary symptom; however, lesions can develop throughout the body, potentially on all organs with mucous membranes. Patients with PLGD-1 may require lifelong treatment.

"We at Kedrion Biopharma appreciate our ongoing partnership with Soleo Health, especially with our latest specialty pharmaceutical, RYPLAZIM. We are confident that our continued collaboration will further improve the lives of patients suffering from PLGD-1 to ensure this essential medication reaches those who need it most," asserted Bob Rossilli, chief commercial officer of Kedrion Biopharma.

"We take pride in being among the few selected specialty pharmacy providers administering RYPLAZIM to PLGD-1 patients. Complex conditions like PLGD-1 require our clinical excellence and extensive knowledge to ensure patients receive appropriate access to treatment while simplifying their complex care. We are thankful for our relationship with Kedrion and the opportunity to make a significant difference in these patients’ lives," explained Drew Walk, chief executive officer of Soleo Health.

For more information about receiving RYPLAZIM therapy and services through Soleo Health, contact the Company at phone 844.547.8600 or fax 380.257.2419.

About Soleo Health

Frisco, Texas-based Soleo Health is a leading national provider of complex specialty pharmacy services administered in the home or at alternate sites of care. Soleo Health’s interdisciplinary team comprises highly experienced clinical pharmacists, registered nurses, reimbursement specialists and patient care ambassadors collaborating with its referring partners.

The Company optimizes patient access solutions and delivers comprehensive services, leading to quantifiable clinical and economic value, resulting in positive patient experiences. Soleo Health has 26 pharmacy locations with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs and The Joint Commission. Additionally, the Company operates more than 30 infusion centers throughout the U.S.

Visit www.soleohealth.com or connect with Soleo Health on LinkedIn, Facebook and X for more information.